Results for: Healthcare

The over-the-counter (OTC) drug market is experiencing steady growth due to increasing demand for self-medication. The convenience and accessibility of OTC drugs make them a popular choice for treating minor ailments such as cough, cold, allergies, pain, fever, acidity, diarrhea, and skin-related conditions. However, concerns over substance abuse, incorrect diagnosis, and other health issues highlight the importance of proper usage and professional advice when using OTC drugs.

The OTC drug market is witnessing increased competition due to patent expiry concerns and the rising popularity of generic alternatives. Pharmaceutical companies are responding by focusing on innovation and strategic partnerships to maintain market share. The growing geriatric population and increasing B2C spending are also contributing to the market’s growth.

Key players in the OTC drug market include Abbott Laboratories, AstraZeneca Plc, Bayer AG, GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Novartis AG, Pfizer Inc., and Sanofi SA. These companies are implementing strategic measures such as alliances, partnerships, mergers, and acquisitions to capitalize on market opportunities.

A new study has found that hospital patients who are treated by women doctors are less likely to die and to be readmitted. The research, published in the journal Annals of Internal Medicine, found that the mortality rate for female patients was 8.15 per cent when treated by women physicians in comparison to 8.38 per cent when the doctor was male – which researchers deem a “clinically significant” difference. The mortality rate for male patients treated by female doctors was 10.15 per cent – less than the 10.23 per cent rate for male physicians.

The global biomarkers market is experiencing significant growth due to the increasing demand for companion diagnostics in the detection and treatment of various fatal diseases. This market is witnessing substantial research investments in the areas of Prostate and Lung cancer, Infectious disease diagnosis, Neurological diseases, and Cardiac problems. Product innovations and biomarker advancements are crucial in early detection, enabling the identification of the physiological state of cells and the activation of active genes.

Customer Relationship Management (CRM) systems are transforming healthcare by enhancing patient engagement, personalizing treatment plans, and streamlining operations. With the increasing demand for personalized services, CRM solutions enable healthcare providers to utilize data from various sources to tailor care to each patient’s unique needs. By leveraging social profiles, behavioral data, medical history, and other relevant information, CRM systems empower healthcare professionals to develop individualized treatment plans and provide real-time updates on prescriptions, precautions, and reports. Additionally, CRM tools facilitate account management, loyalty points, and rewards, enhancing patient retention and satisfaction.

A study of over 700,000 elderly patients found that those treated by female doctors were less likely to die within 30 days of admission or be readmitted within 30 days of discharge. The effect was particularly pronounced for female patients.

Tampa General Hospital’s (TGH) new TGH Crystal River board of managers will oversee operations and provide guidance for leadership. The board will ensure that the needs of the Citrus County community are met while honoring its history and traditions. The board includes healthcare specialists, community leaders, and TGH leadership.

The Federal Reserve’s focus on interest rates to combat inflation may not be effective given the shifting drivers of inflation. Healthcare, housing, and insurance costs are significant contributors to inflation, and addressing the structural issues and price-fixing in these sectors is crucial. Reliance solely on monetary policy may not suffice, and a broader approach considering sectoral factors is necessary.

Despite its continued underperformance in the healthcare sector, JNJ remains a fundamentally strong company with robust profitability and a well-diversified business. Its focus on Innovative Medicine and MedTech segments, along with recent acquisitions in cardiology, provides growth opportunities. While challenges related to Stelara biosimilars and talc-related liabilities persist, JNJ’s strong balance sheet and commitment to M&A provide a solid foundation. Investors with a value and income focus may find JNJ’s current levels attractive, offering a potentially favorable risk/reward entry point.

Governor Kathy Hochul has signed legislation to eliminate insulin cost-sharing for New Yorkers with state-regulated health insurance plans, saving an estimated $14 million in 2025 alone. The budget also includes a $37 billion Medicaid investment plan, support for pregnant mothers, and protections against medical debt lawsuits for low-income individuals.

Medical genetics company Invitae has released its 2024 Environmental, Social and Governance (ESG) Report, showcasing its commitment to improving healthcare through genetic information and outlining key achievements in ESG initiatives for fiscal year 2023.